Drugs / Eveotox
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06937944 | Apr → Dec 2025 overdue | — | JHM BioPharma (Tonghua) Co. , Ltd. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07242300 Comparator | Jan → Dec 2026 expected | focal stiff limb syndrome | JHM BioPharma (Tonghua) Co. , Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eveotox | “Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .” NCT07242300 ↗ |
| Known as | Recombinant Botulinum Toxin Type A | “Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .” NCT07242300 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Rcombinant botulinum toxin type A for injection（Eveotox)” NCT06937944 ↗ |
| Route | Other | “Eveotox, 20 Units, divided into five injections into the glabellar area” NCT06937944 ↗ |